Introduction
In this booklet, we describe an echocardiographic protocol for patients with chronic pulmonary hypertension. It is assumed that the minimum standards for echocardiography laid out by the British Society of Echocardiography (BSE) will be adhered to when undertaking echocardiography.
Many of the measurements we describe here for the identification of pulmonary hypertension and assessment of right ventricular function are part of the minimum dataset recommended by the BSE or can be obtained from views which are part of the basic protocol. Figure 1 . Algorithm for investigating pulmonary hypertension using transthoracic echocardiography. AT, acceleration time; IVC, inferior vena cava; IVRT, isovolumic relaxation time; LV, left ventricle; PAP, pulmonary artery pressure; PLAX, parasternal long axis; RA, right atrium; RV, right ventricle; RVSP, right ventricular systolic pressure; RVOT, right ventricular outflow tract; TAPSE, tricuspid annular plane systolic excursion; V PR, pulmonary regurgitant velocity; VTR, tricuspid regurgitant velocity.
Pulmonary Arterial Hypertension (PAH)
Is pulmonary hypertension suspected?
V TR ≥ 2.6 m/sec* 1 End-diastolic V PR › 1.0 m/sec 5, 6 RV ≥ 1/2 LV from PLAX 7 RVOT AT ‹ 105 msec 8, 9, 10 TAPSE ‹ 20 mm 9, 11-14, 28, 29 RV IVRT › 75 msec 9, [15] [16] [17] IVC › 20 mm & ‹ 50% inspiratory collapse 9 If one or more features identified, pulmonary hypertension may be present Consider right heart assessment protocol Assess associated causes RA volume 9, 18, 19 RV myocardial performance index 9, [20] [21] [22] Tissue Doppler Index of RV free wall 9, [15] [16] [17] 23 Eccentricity Index (end-systolic and diastolic) 9, 24, 25 Cardiac output 26, 27 Pulmonary vascular resistance 26, 27 Congenital heart disease (in particular, exclude pulmonary stenosis)
Valvular heart disease (in particular, mitral valve) LV systolic/diastolic dysfunction * In patients over the age of 60, a VTR ≥ 2.9 m/sec is used as a cut-off value 1 
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Pulmonary Hypertension Echocardiographic Protocol Pulmonary hypertension may be associated with a number of conditions (Table 1) . A multimodality approach is required to make the correct diagnosis, with particular reliance on imaging techniques and cardiac catheterisation [2] [3] [4] . A detailed echocardiographic assessment is required, not just to identify pulmonary hypertension, but also to identify underlying contributing pathology.
In particular, it has a crucial role in identifying left-sided cardiac disease and congenital heart disease and an echocardiogram performed for the assessment of pulmonary hypertension should not ignore these aspects. The protocol described in this booklet will not include a description of how to assess these conditions.
In addition to providing essential diagnostic information, transthoracic echocardiography is used to assess severity of right ventricular dysfunction, providing prognostic information and a non-invasive means of following disease progression or response to therapy. As discussed in more detail in Echocardiography Reporting, isolated abnormalities on echocardiography should be interpreted with caution.
Classically, pulmonary hypertension is suspected when the estimated pulmonary artery systolic pressure, calculated from the tricuspid regurgitant velocity, is elevated, however, this may be underestimated due to an insufficient envelope or eccentric jet. Alternatively, it may be low due to a failing right ventricle.
Consequently, when pulmonary hypertension In a volume-loaded right ventricle with diastolic dysfunction and high end-diastolic pressures, the septum will flatten in diastole. These changes will impact on both left ventricular systolic and diastolic function.
In acute pressure-loading, such as pulmonary embolic disease, the right ventricle will dilate and its free wall will become hypokinetic, but chronic progressive pressure-loading, as in pulmonary hypertension, will lead to right ventricular remodeling, notably hypertrophy. The process is not like the physiological hypertrophy of an athlete's heart, but will also result in myocardial Right Ventricular Pathophysiology 3.0 -4.0 2.7 -3.8 - Table 3 . Normal range of measurements.
In normal subjects, the anterior right ventricular wall is usually thin and its mass is less than one Tricuspid annulus (cm) In the four chamber view, the interatrial septum and interventricular septum can be clearly delineated. As for the parasternal short axis of the interatrial septum, "drop-out" artefact is commonly seen in the region of fossa ovalis. This should not be mistaken for an atrial septal defect. The changes seen in pulmonary hypertension in this view are as described in previous sections. LV eccentricity index at end-systole LV eccentricity index at end-diastole The normal expected upper limit of PASP depends on age and body mass index (BMI). In the largest study to date, the estimated upper 95% limit for PASP was 37.2 mmHg in low-risk subjects (VTR 2.6 m/sec), whereas the estimated upper 95% limit for subjects aged 60 and over was 43.6 mmHg (VTR 2.9 m/sec). In those with a BMI › 30 kg/m 2 the limit was 40 mmHg (VTR 2.8 m/sec). In all these measurements, right atrial pressure was assumed to be 10 mmHg.
A number of studies have highlighted the problem of relying solely on estimates of PASP from echocardiography to diagnose/exclude pulmonary hypertension 42, 43 . In patients with scleroderma being screened for pulmonary hypertension, a cut-off VTR of 2.7 m/sec has a sensitivity of 88% for the detection of pulmonary hypertension 42 . Some of the patients "missed" using this cut-off had mean PAP › 40 mmHg.
Note that in cases of severe free-flow tricuspid regurgitation, the Bernoulli equation is not valid and the tricuspid regurgitant velocity will underestimate the transtricuspid pressure gradient: however, the severity of the tricuspid regurgitation is predictive of survival regardless of the PASP, irrespective of the underlying disease 44 . Severity may be assessed by a number of measurements, including assessment of the structure of the valve, jet area (Table 11) ≥ 0.9 Table 11 . Quantification of tricuspid regurgitation 45 . RV fractional area change (%) 32 -60 ‹ 32 Table 12 . Two-dimensional measurements of right ventricular area
Figure 19a. Measurement of left ventricular eccentricity index in end-diastole (EI ED ).

Figure 19b. Measurement of left ventricular eccentricity index in end-systole (EI ES ).
Figure 20. Examples of the effects of pressure-loading (top two panels) and volume-loading (bottom two panels) of the right ventricle on the eccentricity index of the left ventricle.
Pulmonary Hypertension Echocardiographic Protocol IVRT is discussed further below.
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Transtricuspid inflow (E wave deceleration)
Deceleration of inflow of the E wave is measured TDI can also be used to derive the same parameters as colour Doppler, but only one view is required (Figure 23 ).
*MPI should be indexed for heart rate. Figure 21 ). The patient has to be in sinus rhythm and the velocities are indexed to the heart rate.
Figure 22. Tricuspid inflow from valve opening to closure (TVC-O) is the sum of isovolumic contraction time (IVCT), ejection time (ET) and isovolumic relaxation time (IVRT). The ejection time -as measured from the short axis RVOT view -is subtracted from TVc-o and the result is divided by ET to give MPI.
The S' wave velocity is normally greater than 12
cm/sec, and we consider a cut-off value of 11.5 cm/sec, below which right ventricular myocardial function may be impaired.
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*S' wave velocity should be indexed for heart rate. (Table 9 :
Difference in measurements between pressure and volume loading). continuous-wave Doppler is used to determine the peak tricuspid regurgitant velocity (VTR) as described above: the highest velocity is used.
In patients with atrial fibrillation, the average of five measurements should be taken.
PVR (Wood units) = 10.(VTR/VTIRVOT) + 0.16
This measurement has been shown to correlate well with PVR measured at cardiac catheterisation over a range of right and left atrial pressures.
When investigating potential cases of idiopathic PAH at cardiac catheterisation, a vasodilator (inhaled nitric oxide, intravenous prostacyclin or adenosine) is given to identify a subgroup which may respond to long-term treatment with calcium channel blockers. A positive vasodilator response is defined by a drop in mean pulmonary arterial pressure by more than 10 mmHg to less than 40 mmHg, with a stable or increasing cardiac output 47 . As yet, echocardiography has not been validated to identify this subgroup and therefore
should not be used outside the research setting.
A value of VTR/VTIRVOT less than 0.2 has a 94% sensitivity for a PVR of less than 2 Wood Units at Disease, there is a wide range of defects resulting in complex physiology which one needs to be familiar with in order to correctly judge disease severity and effects of therapy; an overview is given in Table 13 . 
